• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Power3 Chairman/CEO Steven Rash to Discuss Progress in Early Detection Blood Testing for Breast Cancer and Neurodegenerative Diseases on MNI.Com Tomorrow at 9:00 A.M. CDT

Posted on: Monday, 17 July 2006, 09:00 CDT

Steven Rash, chairman and CEO of Power3 Medical Products, Inc. (PWRM.PK), a leading proteomics company that develops and commercializes early detection diagnostic tests for breast cancer and neurodegenerative diseases, will discuss his company's progress in developing blood-based early detection testing in an online radio interview available worldwide tomorrow (Tuesday).

Mr. Rash will be a guest on Market News First (www.MN1.com) at 9 a.m. CDT, interviewed by the Market News First Team, led by Mike "The Analyst" Willingham and Dick Hunter. He will discuss Power3's position as a leader in its field, and its goal of successfully commercializing its tests.

"Power 3 is happy to be on the air on a program focused on microcaps," said Mr. Rash, whose company made international news earlier this year when it when it released results of a survey about breast cancer awareness and detection technology. The independently-conducted study showed a strong desire for blood-based early-detection testing and a low awareness of the limitations of mammography. Power3 also made news when it announced that it was focusing development efforts for early-detection breast cancer tests on blood serum, the platform it successfully used for its NuroPro(R) neurodegenerative tests, with more than 650 patient and control samples.

"We feel strongly that blood serum as a single platform is the best medium for the development and commercialization of proteomics diagnostic tests," said Mr. Rash. "Power3 is indebted to Mr. Willingham, Mr. Hunter and Market News First for devoting time to talking about the importance of Power3's work in developing early detection blood-based tests for breast cancer and neurodegenerative diseases.

About Power3 Medical Products

Power3 Medical Products, Inc. (PWRM.PK, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases, through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease, and its identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art proteomics laboratory in The Woodlands (Houston), Texas.

About MN1.com

Market News First (www.MN1.com) is an online microcap news provider which brings investors current up to speed news on the microcap market. Market News First is the only online live radio web site that brings real microcap news to investors and features live interaction with companies from the Bulletin Board, Pink Sheets, and Amex. Through daily live interviews air on MN1.com, Market First brings listeners up to date on established companies and informs investors about the newest opportunities in the microcap market. Market News First's one-on-one interviews with presidents, CEOs and CFOs of microcaps, broadcasted via its Website, deliver answers to the questions that investors would ask and provide insight into present condition and future plans.

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

Source: Business Wire

More News in this Category